Abstract
Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease (ILD) relating to specific occupational, environmental or medication exposures. Disease behaviour is influenced by the nature of exposure and the host response, with varying degrees of lung inflammation and fibrosis seen within individuals. The differentiation of HP from other ILDs is important due to distinct causes, pathophysiology, prognosis and management implications. This Thoracic Society of Australia and New Zealand (TSANZ) position statement aims to provide an up-to-date summary of the evidence for clinicians relating to the diagnosis and management of HP in adults, in the Australian and New Zealand context. This document highlights recent relevant findings and gaps in the literature for which further research is required.
| Original language | English |
|---|---|
| Pages (from-to) | 1023-1046 |
| Number of pages | 24 |
| Journal | Respirology |
| Volume | 29 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 2024 |
Bibliographical note
Copyright the Author(s) 2024. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.Keywords
- clinical respiratory medicine
- environmental and occupational health and epidemiology
- hypersensitivity pneumonitis
- inflammation
- interstitial lung disease
- pulmonary fibrosis
Fingerprint
Dive into the research topics of 'Diagnosis and management of hypersensitivity pneumonitis in adults: a position statement from the Thoracic Society of Australia and New Zealand'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver